<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Swerdlow NR</submitter><funding>NIMH NIH HHS</funding><pagination>140-148</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8514598</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>53(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Auditory frequency modulation learning ('auditory learning') is a key component of targeted cognitive training (TCT) for schizophrenia. TCT can be effective in enhancing neurocognition and function in schizophrenia, but such gains require significant time and effort and elude many patients.&lt;h4>Methods&lt;/h4>As a strategy to increase and/or accelerate TCT-induced clinical gains, we tested the dose- and time-course effects of the pro-attentional drug, amphetamine (AMPH; placebo, 2.5, 5 or 10 mg po; within-subject double-blind, order balanced) on auditory learning in schizophrenia patients [&lt;i>n&lt;/i> = 32; M:F = 19:13; age 42.0 years (24-55)]. To understand predictors and/or mechanisms of AMPH-enhanced TCT, we also measured auditory fidelity (words-in-noise (WIN), quick speech</pubmed_abstract><journal>Psychological medicine</journal><pubmed_title>Auditory discrimination and frequency modulation learning in schizophrenia patients: amphetamine within-subject dose response and time course.</pubmed_title><pmcid>PMC8514598</pmcid><funding_grant_id>R01 MH059803</funding_grant_id><funding_grant_id>R33 MH123603</funding_grant_id><funding_grant_id>R25 MH101072</funding_grant_id><funding_grant_id>R01 MH094320</funding_grant_id><pubmed_authors>Molina JL</pubmed_authors><pubmed_authors>Bhakta SG</pubmed_authors><pubmed_authors>Kotz J</pubmed_authors><pubmed_authors>Talledo J</pubmed_authors><pubmed_authors>Vinogradov S</pubmed_authors><pubmed_authors>Benster L</pubmed_authors><pubmed_authors>Light GA</pubmed_authors><pubmed_authors>Swerdlow NR</pubmed_authors></additional><is_claimable>false</is_claimable><name>Auditory discrimination and frequency modulation learning in schizophrenia patients: amphetamine within-subject dose response and time course.</name><description>&lt;h4>Background&lt;/h4>Auditory frequency modulation learning ('auditory learning') is a key component of targeted cognitive training (TCT) for schizophrenia. TCT can be effective in enhancing neurocognition and function in schizophrenia, but such gains require significant time and effort and elude many patients.&lt;h4>Methods&lt;/h4>As a strategy to increase and/or accelerate TCT-induced clinical gains, we tested the dose- and time-course effects of the pro-attentional drug, amphetamine (AMPH; placebo, 2.5, 5 or 10 mg po; within-subject double-blind, order balanced) on auditory learning in schizophrenia patients [&lt;i>n&lt;/i> = 32; M:F = 19:13; age 42.0 years (24-55)]. To understand predictors and/or mechanisms of AMPH-enhanced TCT, we also measured auditory fidelity (words-in-noise (WIN), quick speech</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2026-03-27T16:14:15.816Z</modification><creation>2025-08-28T03:07:12.4Z</creation></dates><accession>S-EPMC8514598</accession><cross_references><pubmed>33849683</pubmed><doi>10.1017/S0033291721001239</doi></cross_references></HashMap>